Plant-Based Nutraceutical Strategies for Memory Enhancement and Neuroprotection: Mechanistic Insights and Preclinical Evidence

One of the biggest global public health and socioeconomic issues is cognitive decline and neurodegenerative illnesses. Memory, executive function, language, and behavior impairment, as well as progressive neuronal degeneration and synaptic loss, are hallmarks of disorders like Parkinson's and Alzheimer's [1]. Alzheimer's disease is the primary cause of cognitive impairment in older persons, accounting for between 60 and 70 percent of all dementia cases worldwide. More than 55 million individuals worldwide suffer from dementia, according to recent epidemiological estimates, and this figure is expected to rise to over 130 million by 2050 as a result of demographic aging and longer life expectancies [2].

The financial cost is similarly significant. The yearly worldwide cost of dementia care, which includes medical bills, social services, and unpaid caring, has topped $1 trillion USD and is predicted to grow over the next several decades. These diseases cause caregivers and families to experience significant psychological and social stress in addition to financial pressure [3]. In addition to neurodegenerative illnesses with a clinical diagnosis, 15–20% of people over 60 suffer from moderate cognitive impairment (MCI), which frequently acts as a bridge between dementia and normal aging [4]. Cognitive diseases are becoming more common due to a number of factors, including age-related cognitive decline, stress-induced memory loss, vascular cognitive dysfunction, diabetes-related cognitive deficiencies, and neurocognitive alterations linked with metabolic syndrome. Cognitive decline results from intricate and interconnected pathogenic pathways at the molecular and cellular levels [5].

Oxidative stress is a major factor because, although making up just 2% of body weight, the brain uses around 20% of all oxygen, making it very susceptible to damage from reactive oxygen species (ROS) [6]. In neurodegenerative diseases, elevated lipid peroxidation, protein oxidation, and DNA damage have all been repeatedly noted. A vicious cycle of brain damage is created when mitochondrial malfunction worsens energy deficiencies and raises ROS production. Pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 are continuously produced as a result of chronic neuroinflammation caused by activated microglia and astrocytes [7]. Excessive glutamate signaling excitotoxicity causes calcium overload and neuronal death. Memory impairments are directly caused by impaired cholinergic neurotransmission, specifically decreased acetylcholine levels in the cortex and hippocampus.

Furthermore, tau protein hyperphosphorylation and the pathological buildup of amyloid-beta plaques impair synaptic integrity and neural transmission. Neuronal survival and synaptic plasticity are hampered by decreased levels of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) [8]. The fact that mitochondrial impairment, oxidative stress, inflammation, protein aggregation, and synaptic dysfunction all coexist highlights how complex cognitive decline is. As a result, treatment techniques that focus on a single route are frequently insufficient, highlighting the necessity of multitargeted therapies that may simultaneously modulate many interrelated pathways [9].

1. 1. Limitations of Current Pharmacological Therapies

Current pharmaceutical therapies do not alter the condition; rather, they merely provide symptomatic alleviation, despite advancements in neuroscience. For example, NMDA receptor antagonists like memantine and acetylcholinesterase inhibitors like donepezil are frequently used in the treatment of Alzheimer's disease [10]. Although these medications may slow the course of symptoms or offer slight cognitive enhancements, their benefits are transient and frequently linked to negative side effects like nausea, lightheadedness, and cardiovascular issues. Furthermore, no presently authorized drug reliably stops neuronal deterioration or recovers lost cognitive function, and treatment response varies greatly among individuals. The critical need for safer, multitargeted, and preventative methods is highlighted by this therapeutic constraint [11].

1. 2. Rising Interest in Plant-Based Nutraceuticals

Enthusiasm in plant-based nutraceuticals for cognitive health has increased as a result of growing discontent with traditional therapy. Bioactive substances obtained from food or medicinal plants that provide health advantages beyond simple nourishment are known as nutraceuticals. The antioxidant, anti-inflammatory, anti-apoptotic, and neurotrophic qualities of these substances are being investigated more and more [12].

Ayurveda, Traditional Chinese Medicine, and other ethnomedical systems have long utilized traditional medicinal herbs including Bacopa monnieri, Ginkgo biloba, Withania somnifera, and Curcuma longa to improve brain clarity and memory. According to recent pharmacological research, its phytochemicals which include phenolic compounds, alkaloids, terpenoids, and flavonoids modify a number of neuronal pathways that are important for cognitive function [13].

1. 3. Concept of Neuroprotection and Memory Enhancement

By maintaining cellular homeostasis, mitochondrial function, and synaptic integrity, neuroprotection refers to methods that stop or reduce neuronal damage. It includes reducing excitotoxicity, activating endogenous antioxidant systems like the Nrf2 pathway, inhibiting neuroinflammatory signals (like the NF-κB pathway), and modulating oxidative stress [14].

On the other hand, memory enhancement aims to improve hippocampus function, neurotransmitter balance, synaptic plasticity, and learning processes. Acetylcholinesterase inhibition, brain-derived neurotrophic factor (BDNF) overexpression, long-term potentiation (LTP) augmentation, and defense against amyloid-beta-induced synaptic toxicity are important processes. Crucially, pleiotropic effects are frequently seen by plant-based nutraceuticals, which concurrently target memory-enhancing and neuroprotective pathways [15].

1. 4. Aim and Scope of the Review

With a focus on molecular insights and preclinical data, this review aims to thoroughly investigate plant-based nutraceutical techniques for memory improvement and neuroprotection. The main phytochemicals and medicinal plants, their molecular targets, and the signaling pathways involved in cognitive regulation will all be examined in this review [16]. It will also assess results from animal and in vitro models of memory impairment, talk about standardization and bioavailability issues, and point up areas for further research. This study aims to offer a scientific basis for the logical development of plant-derived nutraceuticals as prospective therapeutic or preventative methods for neurodegenerative diseases and cognitive decline by fusing experimental data with molecular knowledge [17].

2. METHODOLOGY OF LITERATURE SEARCH
   1. Data Sources

A comprehensive and systematic literature search was conducted to identify relevant studies evaluating plant-based nutraceuticals for memory enhancement and neuroprotection. Multiple electronic databases were searched to ensure broad coverage of biomedical, pharmacological, and interdisciplinary research. The primary databases included PubMed, Scopus, Web of Science, and ScienceDirect [18].

To capture grey literature and minimize publication bias, additional searches were performed using Google Scholar. Reference lists of relevant review articles and selected primary studies were also manually screened to identify additional eligible publications. The search covered studies published up to the most recent available date prior to manuscript preparation [19].

1. 2. Search Strategy

The search strategy was designed to identify studies focusing on phytochemicals, herbal extracts, and nutraceutical compounds with reported cognitive or neuroprotective effects. Keywords and controlled vocabulary terms were combined using Boolean operators (AND, OR) to refine the search and increase specificity.

Representative search strings included:

• “Plant-based nutraceuticals” AND “memory enhancement”
• “Neuroprotection” AND “phytochemicals”
• “Cognitive impairment” AND “polyphenols”
• “Herbal extracts” AND “Alzheimer’s disease”

Additional combinations incorporated related terms such as “oxidative stress,” “neuroinflammation,” “synaptic plasticity,” “mitochondrial dysfunction,” and “animal models.” Truncation and wildcard symbols were applied where appropriate to capture variations in terminology.

1. 3. Inclusion Criteria

Studies were included based on predefined eligibility criteria to ensure scientific rigor and relevance. Eligible publications were:

• Peer-reviewed original research articles, including in vitro, in vivo, and other preclinical experimental studies.
• Published in the English language.
• Focused on evaluating cognitive outcomes (e.g., memory, learning, behavioral performance) or neuroprotective effects.
• Investigating mechanistic pathways such as oxidative stress modulation, anti-inflammatory signaling, mitochondrial protection, cholinergic regulation, or synaptic plasticity.

Both mechanistic cellular studies and animal behavioral models of cognitive impairment were considered to provide a comprehensive overview of preclinical evidence.

1. 4. Exclusion Criteria

Studies were excluded if they met any of the following conditions:

• Conference abstracts, editorials, commentaries, or letters without complete experimental data.
• Non-English publications.
• Studies lacking clear mechanistic insight or measurable cognitive outcomes.
• Duplicate records identified across multiple databases.

Review articles were excluded from primary data synthesis but were used for background information and reference tracking.

1. 5. Study Selection and Data Extraction

The study selection process was conducted in multiple stages. Initially, titles and abstracts were screened to exclude clearly irrelevant articles. Potentially eligible studies were then subjected to full-text assessment to determine final inclusion.

For each selected study, relevant data were systematically extracted, including plant source, specific bioactive compounds, type of extract, experimental model (cell line or animal model), dosage and duration of treatment, biomarkers assessed (e.g., oxidative stress markers, inflammatory cytokines, antioxidant enzymes), and reported cognitive or behavioral outcomes. This structured methodology ensured transparency, reproducibility, and comprehensive coverage of the available preclinical evidence supporting plant-based nutraceutical strategies for memory enhancement and neuroprotection [14].

3. PATHOPHYSIOLOGY OF COGNITIVE DECLINE AND NEURODEGENERATION

Complex, interconnected molecular and cellular abnormalities that gradually reduce neuronal survival, synaptic transmission, and network connectivity are the cause of cognitive decline and neurodegenerative diseases. Pathological pathways that overlap between conditions like Parkinson's disease and Alzheimer's disease include oxidative stress, chronic neuroinflammation, protein aggregation, mitochondrial dysfunction, cholinergic deficiencies, and impairment of synaptic plasticity. These mechanisms work in concert to hasten cognitive decline and neuronal damage [20].

1. 1. Oxidative Stress in Neuronal Damage

A major factor in the development and advancement of neurodegeneration is oxidative stress. Because of its high oxygen demand (about 20% of total body oxygen), high lipid content, and comparatively limited antioxidant ability, the brain is especially susceptible. Overproduction of reactive oxygen species (ROS) causes DNA damage, protein oxidation, and lipid peroxidation [21]. Neurodegenerative diseases have been repeatedly linked to elevated levels of oxidized nucleic acids, 4-hydroxynonenal (4-HNE), and malondialdehyde (MDA).
A vicious cycle of oxidative damage is created when the mitochondrial electron transport chain malfunctions, increasing the generation of ROS [22]. By causing cytochrome c release and caspase activation, oxidative stress damages membrane integrity, inhibits ion channel function, and initiates apoptotic pathways. Cumulative oxidative damage impairs neuronal survival over time and is a direct cause of memory loss [23].

1. 2. Neuroinflammation: Microglial Activation and Cytokines

Another indicator of cognitive deterioration is chronic neuroinflammation. When oxidative stress, protein aggregation, or neuronal damage occur, microglia—the central nervous system's resident immune cells—become continuously active. Pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 are released by activated microglia along with nitric oxide and other ROS [24].

Prolonged stimulation results in chronic inflammatory signaling, synaptic dysfunction, and neuronal death, even if acute inflammatory responses may be helpful at first. The inflammatory cascade is sustained by the activation of transcription factors like NF-κB, which leads to progressive neurodegeneration. Astrocyte reactivity interferes with neuronal-glial communication and intensifies inflammatory reactions [25].

1. 3. Amyloid-β Aggregation and Tau Hyperphosphorylation

One of the main characteristics of Alzheimer's disease pathogenesis is protein aggregation and misfolding. Amyloid-β (Aβ) peptides build up extracellularly to create plaque, which disrupts synaptic transmission and sets off inflammatory reactions [26]. Because they cause oxidative stress and disturb calcium homeostasis, Aβ oligomers are especially hazardous.
Neurofibrillary tangles are caused by aberrant hyperphosphorylation of the tau protein within cells. Axonal transport and neural transmission are disrupted by tau dysfunction, which also affects microtubule stability. Progressive cognitive decline, neuronal shrinkage, and synaptic loss are all caused by the combined load of tau tangles and Aβ plaques [27].

1. 4. Mitochondrial Dysfunction

Calcium homeostasis and neural energy metabolism depend on mitochondria. Reduced ATP synthesis, decreased oxidative phosphorylation, and increased ROS formation are all consequences of mitochondrial dysfunction in neurodegenerative diseases. Cellular integrity is further jeopardized by changes in mitochondrial dynamics, such as diminished fusion or excessive fission [28].

When damaged mitochondria are cleared by defective mitophagy, malfunctioning organelles accumulate, increasing oxidative stress and apoptosis. High-demand brain areas like the cortex and hippocampus, which are critical for learning and memory functions, are especially impacted by energy deficiencies [29].

1. 5. Cholinergic Deficit Hypothesis

According to the cholinergic hypothesis, decreased acetylcholine levels in the hippocampus and cerebral cortex are closely linked to cognitive loss, especially in Alzheimer's disease. Memory encoding and retrieval are hampered by the reduction in neurotransmitter availability caused by cholinergic neuron degeneration in the basal forebrain [30]. Neurotransmitter depletion is made worse by increased activity of acetylcholinesterase (AChE), the enzyme that breaks down acetylcholine. The therapeutic use of AChE inhibitors to treat symptoms is based on this shortcoming; however, the underlying neurodegenerative processes are not addressed by these therapies [31].

1. 6. Synaptic Plasticity Impairment

Learning and memory formation depend on synaptic plasticity, especially long-term potentiation (LTP). Through protein aggregation, inflammatory signaling, and oxidative damage, neurodegeneration impairs synapse structure and function. Neuronal survival and synaptic remodeling are hampered by decreased expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) [32]. Synaptic connection is further compromised by NMDA receptor dysfunction, aberrant glutamatergic signaling, and dendritic spine loss. Synaptic failure is thought to be the main cause of early memory impairments because synaptic integrity is more important for cognitive function than neuronal quantity alone [33].

 

 

Fig 1: Pathophysiology of Cognitive Decline and Neurodegeneration [34]

6. PRECLINICAL EVIDENCE AND EXPERIMENTAL MODELS

Preclinical studies offer fundamental proof of the plant-based nutraceuticals' capacity to improve memory and preserve the nervous system. These investigations assess behavioral outcomes, molecular indicators linked to cognitive function, and mechanistic pathways using both in vitro and in vivo experimental models.

1. 1. In Vitro Neuronal Cell Line Studies

Neuronal cell lines including PC12, SH-SY5Y, and primary hippocampus neurons are frequently used in in vitro research to investigate the cytoprotective and mechanistic effects of plant bioactives. To mimic neurodegenerative diseases, these models are subjected to oxidative stressors (such hydrogen peroxide), amyloid-β peptides, or inflammatory stimuli [63]. The capacity of phytochemicals to lower the formation of reactive oxygen species, stop apoptosis, stop amyloid accumulation, and alter intracellular signaling pathways such Nrf2, NF-κB, PI3K/Akt, and MAPK is evaluated. Dose-dependent cellular responses and molecular targets may be thoroughly investigated in these regulated systems [64].

1. 2.  Animal Models of Cognitive Impairment

Neuroprotective effects are functionally validated in animal models. While amyloid-β (Aβ)-induced models imitate amyloid toxicity, scopolamine-induced amnesia models are frequently employed to mimic cholinergic dysfunction. Progressive neuropathological symptoms are further replicated in transgenic mice with Alzheimer's disease that produce mutant tau or APP proteins. When given in these models, plant-derived nutraceuticals have been shown to enhance memory and learning, lower the amyloid load, lessen oxidative stress, and suppress neuroinflammation [65].

1. 3.  Behavioral Assessment Paradigms

Standardized behavioral tests are used to assess cognitive ability. Passive avoidance tests examine associative learning and memory consolidation, the Morris water maze measures spatial learning and memory retention, and the Y-maze measures working memory and spontaneous alternation behavior. After receiving phytochemical therapy, improvements in escape latency, alternation percentage, and retention latency are frequently recorded [66].

1. 4.  Biomarkers and Biochemical Parameters

Preclinical research measures cholinergic indicators like acetylcholinesterase (AChE) activity, antioxidant enzymes like superoxide dismutase (SOD), and oxidative stress markers like malondialdehyde (MDA). To assess synaptic plasticity and neuronal survival, neurotrophic factors in particular, brain-derived neurotrophic factor, or BDNF are also measured. Improved cognitive results are consistently correlated with lower levels of MDA and AChE as well as higher expression of SOD and BDNF [67].

1. 5.  Dose–Response Relationships

In preclinical models, dose-dependent effects are commonly seen. Particular dosage ranges usually yield the best cognitive effects, however very high dosages may result in moderate toxicity or decreased efficacy. These results emphasize how crucial uniform dosing procedures and pharmacokinetic assessment are to easing the transition to clinical research [68].

Moreover, variations in extract composition, bioactive content, administration method, and treatment duration can all lead to variations in dose-response relationships. Standardized extracts with predetermined concentrations of active phytochemicals are necessary to guarantee study comparability and repeatability [69]. Furthermore, the effectiveness of treatment is greatly influenced by elements such metabolic stability, blood–brain barrier permeability, bioavailability, and interaction with other signaling pathways. Optimizing translational potential and creating well-structured clinical trials will need thorough pharmacokinetic and pharmacodynamic profiling, which includes determining the minimal effective dosage and no-observed-adverse-effect level (NOAEL) [70].

7. BIOAVAILABILITY, SAFETY, AND FORMULATION APPROACHES

Pharmacokinetic constraints, extract composition heterogeneity, and regulatory obstacles often restrict the clinical translation of plant-based nutraceuticals, despite their excellent mechanistic and preclinical evidence for neuroprotection and memory improvement. Therefore, a thorough grasp of formulation techniques, safety, central nervous system (CNS) distribution, and bioavailability is necessary for effective therapeutic development [71].

1. 1. Challenges in Oral Bioavailability

Despite oral administration is still the most convenient and patient-friendly methods of delivering nutraceuticals, many phytochemicals have low oral bioavailability. Low aqueous solubility, chemical instability in gastrointestinal disorders, restricted intestinal permeability, fast phase I and phase II metabolism, and significant first-pass hepatic clearance are important limiting factors [72]. For example, polyphenolic substances are susceptible to conjugation processes (glucuronidation, sulfation, and methylation) and oxidation, which lowers the amounts of active aglycone forms in the bloodstream [73].

Furthermore, certain phytochemicals can be actively expelled back into the intestinal lumen by efflux transporters such P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs), which further restricts absorption [74]. Variations in gut microbiota across individuals also affect how plant components are biotransformed, producing metabolites with varying biological activities. These intricacies emphasize the necessity of metabolic profile and pharmacokinetic optimization while also contributing to variation in treatment responses [75].

1. 2.  Blood–Brain Barrier Penetration

Sufficient penetration across the blood–brain barrier is essential for neuroprotection and cognitive improvement. Together, endothelial cells, tight junction proteins, astrocytic end-feet, and pericytes make up the BBB, a highly selective interface that prevents xenobiotics from entering the central nervous system. BBB permeability is determined by molecular properties such transporter affinity, hydrogen bonding ability, lipophilicity, and molecular weight (usually less than 500 Da) [76].

The CNS accumulation of many plant-derived chemicals is limited because they are either excessively hydrophilic or substrates of efflux transporters. Additionally, before active forms reach the brain, systemic metabolism might lower their concentration. To increase the effectiveness of CNS targeting, strategies that increase lipophilicity, shield drugs from premature metabolism, or take advantage of receptor-mediated transcytosis pathways are being investigated more and more [77].

1. 3.  Nanoformulations and Advanced Delivery Systems

Novel formulation approaches have been created to get around pharmacokinetic obstacles. Polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, dendrimers, and liposomes are examples of nanotechnology-based systems that enhance solubility, guard against enzymatic degradation, and provide controlled or prolonged release. By using endocytosis or transcytosis processes, these carriers can improve gastrointestinal absorption and make it easier for the BBB to penetrate [78].

By complexing phytochemicals with phospholipids, phytosome technology increases membrane permeability and boosts systemic bioavailability. Micellar systems and cyclodextrin inclusion complexes also improve solubility and stability [79]. In preclinical studies, surface modification of nanoparticles with targeting ligands (such as lactoferrin or transferrin) has occasionally shown enhanced brain delivery. Crucially, these cutting-edge methods may lower necessary dosages while simultaneously improving pharmacokinetic profiles, reducing the possibility of side effects and preserving therapeutic efficacy [80].

1. 4.  Safety and Toxicological Considerations

Because of their natural nature and long history of usage in traditional medicine, plant-based nutraceuticals are usually regarded as safe. Low acute toxicity and high safety margins are frequently reported in preclinical toxicity assessments. However, safety cannot be taken for granted. Excessive consumption may result in hepatotoxicity, gastrointestinal issues, or changes in hematological markers, according to dose escalation studies [81].

Another crucial factor to take into account is herb-drug interactions, especially in older populations where people may be on many drugs [82]. The pharmacokinetics of medications taken together may be impacted by certain phytochemicals that change drug transporter function or influence cytochrome P450 enzymes. To provide thorough safety profiles, long-term safety investigations, evaluations of reproductive toxicity, and post-marketing surveillance are necessary [83].

1. 5.  Standardization and Quality Control

Inconsistency in extract composition is a significant obstacle in nutraceutical research. Phytochemical concentration can be greatly impacted by differences in plant species, geographic origin, cultivation techniques, harvesting time, drying techniques, and extraction solvents. The repeatability of clinical results and experimental discoveries is compromised in the absence of standardization [84].

Regulatory compliance, uniformity, and dependability are guaranteed by standardized extracts with specified amounts of marker chemicals. For quality control, sophisticated analytical methods including mass spectrometry, fingerprint profiling, and high-performance liquid chromatography (HPLC) are used. Product safety and consistency are further supported by adherence to Good Manufacturing Practices (GMP) and Good Agricultural and Collection Practices (GACP). Bridging the gap between experimental research and evidence-based clinical application will need the establishment of verified pharmacokinetic parameters, therapeutic dosage ranges, and bioequivalence criteria [85].

8. CONCLUSION AND FUTURE PERSPECTIVES

Preclinical data is mounting that plant-based nutraceuticals have the potential to improve memory and provide neuroprotection. These bioactives work mechanistically by addressing the fundamental pathophysiological mechanisms that underlie cognitive decline through integrated and multitarget pathways. By scavenging reactive oxygen species and triggering endogenous antioxidant defenses like the Nrf2 pathway, they reduce oxidative stress. At the same time, they reduce pro-inflammatory cytokines and block NF-κB signaling to control neuroinflammation. Additionally, several phytochemicals reduce tau hyperphosphorylation, restrict β-secretase activity, interfere with amyloidogenic processing, and improve cholinergic neurotransmission by inhibiting acetylcholinesterase. Crucially, by upregulating BDNF and modifying the CREB, PI3K/Akt, and MAPK pathways, a number of plant chemicals support neurogenesis and synaptic plasticity. Plant-based nutraceuticals differ from single-target pharmaceutical medicines due to their pleiotropic mechanism of action.

1. 1. Translational Potential

Phytochemicals' multitarget properties complement the complex nature of neurodegenerative diseases. Learning, memory retention, oxidative biomarkers, inflammatory mediators, and synaptic signaling are all continuously improved in preclinical models. Translational feasibility is being strengthened by advanced formulation techniques that improve bioavailability and central nervous system penetration, such as standardized extracts and nano-delivery systems. Variability in extract composition and pharmacokinetics, however, continues to be a hurdle that has to be methodically addressed.

1. 2. Need for Well-Designed Clinical Trials

There is currently a lack of strong clinical validation despite encouraging experimental evidence. Randomized, double-blind, placebo-controlled trials with sufficient sample numbers and defined outcome measures have to be given top priority in future studies. The identification of therapy benefits may be enhanced by stratification according to metabolic state, genetic risk factors, and illness stage. Clinical mechanistic interpretation will be improved by combining biomarker-based endpoints, such as neurotrophic factors, inflammatory cytokines, and oxidative stress markers, with cognition tests.

1. 3. Multi-Target Nutraceutical Combinations

Combination therapies may provide synergistic advantages due to the intricate and interrelated mechanisms involved in neurodegeneration. Superior neuroprotective results may be achieved by logically combining complimentary phytochemicals that target amyloid disease, oxidative stress, inflammation, and synaptic dysfunction all at once. To guarantee therapeutic efficacy without unfavorable interactions, however, pharmacodynamic interactions, ideal dosage ratios, and safety profiles must be carefully examined.

1. 4. Integration with Preventive Neurology Strategies

Nutraceuticals derived from plants may be useful in preventative neurology, especially for those who are susceptible to age-related cognitive impairment. Nutraceutical strategies may help postpone the start and progression of illness when paired with lifestyle therapies including physical exercise, cognitive training, balanced eating, and metabolic risk management. To optimize therapeutic effect, future studies should investigate early-intervention techniques and long-term preventative approaches. To sum up, plant-based nutraceuticals provide a potential supplemental or adjunct strategy for neuroprotection and memory improvement. Converting mechanistic findings into useful therapeutic applications will need bolstering clinical data, refining formulations, and incorporating these drugs into all-encompassing preventative frameworks.

REFERENCES

1. 1. Borrego-Ruiz A, Borrego JJ. Plant-derived nutraceuticals in mental health and brain function: Mechanisms of action and therapeutic potential. International Journal of Molecular Sciences. 2025 Sep 11;26(18):8849.
   2. Shoaib S, Ansari MA, Fatease AA, Safhi AY, Hani U, Jahan R, Alomary MN, Ansari MN, Ahmed N, Wahab S, Ahmad W. Plant-derived bioactive compounds in the management of neurodegenerative disorders: challenges, future directions and molecular mechanisms involved in neuroprotection. Pharmaceutics. 2023 Feb 23;15(3):749.
   3. May N, de Sousa Alves Neri JL, Clunas H, Shi J, Parkes E, Dongol A, Wang Z, Jimenez Naranjo C, Yu Y, Huang XF, Charlton K. Investigating the therapeutic potential of plants and plant-based medicines: relevance to antioxidant and neuroprotective effects. Nutrients. 2023 Sep 8;15(18):3912.
   4. Gomes TM, Sousa P, Campos C, Perestrelo R, Câmara JS. Secondary bioactive metabolites from foods of plant origin as theravention agents against neurodegenerative disorders. Foods. 2024 Jul 20;13(14):2289.
   5. Grancharova T, Velchev V, Pilicheva B, Zagorchev P. Plant and Plant-Based Compounds as Enhancers of Neurotrophins in the Management of Neurodegenerative Diseases.
   6. Dulary S, Durga B. Neuroprotective Properties of Plant-Based Secondary Metabolites: Molecular Insights into Therapeutics. Indian Journal of Science and Technology. 2025 Nov 16;18(41):3292-9.
   7. Chen JH, Yin X, He H, Lu LW, Wang M, Liu B, Cheng KW. Potential neuroprotective benefits of plant-based fermented foods in Alzheimer's disease: an update on preclinical evidence. Food & Function. 2024;15(8):3920-38.
   8. Aijaz M, Kumar A, Ahmad M, Ansari MA. Plant‐Based Therapies in Parkinson's Disease Management: Mechanisms, Clinical Evidence, and Future Perspectives. Letters in Applied NanoBioScience. 2024;13(3):148.
   9. Kumar R, Pal OP, Kamboj N, Jaiswal A. Phytonutrients in neuroprotection and neurodegenerative disorders. Current Research in Nutrition and Food Science Journal. 2025 Jul 10;13(Special Issue Phytonutrients July 2025):72-96.
   10. Pavlov S, Prajapati SK, Yadav D, Marcano-Rodriguez A, Yadav H, Jain S. Advances in Bioactive Compounds from Plants and Their Applications in Alzheimer’s Disease. Biomolecules. 2025 Dec 19;16(1):7.
   11. Nagori K, Nakhate KT, Yadav K, Ajazuddin, Pradhan M. Unlocking the therapeutic potential of medicinal plants for Alzheimer’s disease: Preclinical to clinical trial insights. Future Pharmacology. 2023 Nov 13;3(4):877-907.
   12. Kure C, Timmer J, Stough C. The immunomodulatory effects of plant extracts and plant secondary metabolites on chronic neuroinflammation and cognitive aging: a mechanistic and empirical review. Frontiers in pharmacology. 2017 Mar 10;8:117.
   13. Wang Y, Wang K, Yan J, Zhou Q, Wang X. Recent progress in research on mechanisms of action of natural products against Alzheimer’s disease: dietary plant polyphenols. International Journal of Molecular Sciences. 2022 Nov 11;23(22):13886.
   14. Aktary N, Jeong Y, Oh S, Shin Y, Sung Y, Rahman M, Ramos Santiago L, Choi J, Song HG, Nurkolis F, Ribeiro RI. Unveiling the therapeutic potential of natural products in Alzheimer’s disease: insig
   15. Aggarwal A, Rajalekshmi R, Aggarwal A, Agrawal DK. Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines. International journal of plant, animal and environmental sciences. 2025 Aug 4;15(3):90.
   16. Kumari N, Anand S, Shah K, Chauhan NS, Sethiya NK, Singhal M. Emerging role of plant-based bioactive compounds as therapeutics in Parkinson’s disease. Molecules. 2023 Nov 14;28(22):7588.
   17. Choudhary N, Tewari D, Nabavi SF, Kashani HR, Lorigooini Z, Filosa R, Khan FB, Masoudian N, Nabavi SM. Plant based food bioactives: A boon or bane for neurological disorders. Critical Reviews in Food Science and Nutrition. 2024 Apr 25;64(11):3279-325.
   18. Goel F. Exploring the therapeutic role of Moringa oleifera in neurodegeneration: antioxidant, anti-inflammatory, and neuroprotective mechanisms: Exploring the therapeutic role of Moringa oleifera in neurodegeneration. Inflammopharmacology. 2025 Jul;33(7):3653-69.
   19. Godos J, Carota G, Caruso G, Micek A, Frias-Toral E, Giampieri F, Brito-Ballester J, Velasco CL, Quiles JL, Battino M, Galvano F. Molecular mechanisms underlying the neuroprotective effects of polyphenols: implications for cognitive function. EXCLI journal. 2025 Sep 10;24:1262.
   20. Adhikary K, Ganguly K, Sarkar R, Abubakar M, Banerjee P, Karak P. Phytonutrients and their neuroprotective role in brain disorders. Frontiers in Molecular Biosciences. 2025 Sep 2;12:1607330.
   21. Debnath I, Ghosh S, Bhunia S, Nayak A, Basak S, Nandi S, Bhattacharjee S. Mechanistic insights and therapeutic potential of quercetin in neuroprotection: a comprehensive review of pathways and clinical perspectives. BIO Integration. 2025 Aug 18;6(1):978.
   22. Chen G, Su Y, Chen S, Lin T, Lin X. Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support. Food Science & Nutrition. 2025 Sep;13(9):e70496.
   23. Tkaczenko H, Buyun L, Kołodziejska R, Kamiński P, Kurhaluk N. Neuroactive phytochemicals as multi-target modulators of mental health and cognitive function: an integrative review. International Journal of Molecular Sciences. 2025 Sep 12;26(18):8907.
   24. Raghu SV, Kudva AK, Krishnamurthy RG, Mudgal J, George T, Baliga MS. Neuroprotective effects of dietary plants and phytochemicals against radiation-induced cognitive and behavioral deficits: A comprehensive review of evidence and prospects for future research. Food & function. 2023;14(13):5921-35.
   25. Kalita P, Bhattacharjee B, Sahu RK, Sarma S. Nutraceuticals in Brain Health. InPlant-based Foods and their Implications in Brain Health 2024 Dec 23 (pp. 342-359). CRC Press.
   26. Moukham H, Lambiase A, Barone GD, Tripodi F, Coccetti P. Exploiting natural niches with neuroprotective properties: a comprehensive review. Nutrients. 2024 Apr 26;16(9):1298.
   27. Feng Gu MS, Pan Zhu MM. The effect of plant-derived dietary antioxidants on Alzheimer’s disease: Focus on ferroptosis.
   28. Puri V, Kanojia N, Sharma A, Huanbutta K, Dheer D, Sangnim T. Natural product-based pharmacological studies for neurological disorders. Frontiers in pharmacology. 2022 Nov 7;13:1011740.
   29. Grosso C, Santos M, Barroso MF. From plants to psycho-neurology: unravelling the therapeutic benefits of bioactive compounds in brain disorders. Antioxidants. 2023 Aug 11;12(8):1603.
   30. Davinelli S, Maes M, Corbi G, Zarrelli A, Willcox DC, Scapagnini G. Dietary phytochemicals and neuro-inflammaging: from mechanistic insights to translational challenges. Immunity & Ageing. 2016 Apr 14;13(1):16.
   31. Li W, Yang D, Zhang Z, Wang M, Xu S, Jiang R, Chen J, Wu C, Qian J. Plant food-derived antioxidant nutrients in neuroprotection against chemotherapy-induced neurotoxicity: from molecular mechanisms to clinical applications. Frontiers in Nutrition. 2025 Dec 5;12:1667421.
   32. Gu F, Zhu J, Zhu P, Zou Z. Effects of plant-derived dietary antioxidants on Alzheimer's disease: Focus on ferroptosis. Asia Pacific Journal of Clinical Nutrition. 2025 Nov 26;34(6):922.
   33. Kowalczyk A, Tuberoso CI, Jerković I. Experimental Evidence of Caffeic Acid’s Neuroprotective Activity in Alzheimer’s Disease: In Vitro, In Vivo, and Delivery-Based Insights. Medicina. 2025 Aug 8;61(8):1428.
   34. Sharma MK. Emerging Role of Polyphenols in Nutraceutical Development: Current Insights and Future Directions. InPolyphenol Nutraceuticals and Healthcare 2026 Jan 22 (pp. 313-327). CRC Press.
   35. Regenthal R, Rong P, Krügel U. Nutraceuticals in mental diseases—Bridging the gap between traditional use and modern pharmacology. Current Opinion in Pharmacology. 2021 Dec 1;61:62-8.
   36. Kruszka J, Martyński J, Szewczyk-Golec K, Woźniak A, Nuszkiewicz J. The role of selected flavonoids in modulating neuroinflammation in Alzheimer’s disease: mechanisms and therapeutic potential. Brain Sciences. 2025 May 5;15(5):485.
   37. Zhao D, Simon JE, Wu Q. A critical review on grape polyphenols for neuroprotection: Strategies to enhance bioefficacy. Critical Reviews in Food Science and Nutrition. 2020 Feb 21;60(4):597-625.
   38. Firdaus Z, Singh TD. An insight in pathophysiological mechanism of Alzheimer’s disease and its management using plant natural products. Mini Reviews in Medicinal Chemistry. 2021 Jan 1;21(1):35-57.
   39. Gentile MT, Camerino I, Ciarmiello L, Woodrow P, Muscariello L, De Chiara I, Pacifico S. Neuro-nutraceutical polyphenols: how far are we?. Antioxidants. 2023 Feb 21;12(3):539.
   40. Nagpal D, Nema S, Nagpal S, Pandey MM, Kaushik D, Kathuria H. Management and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?. Antioxidants. 2025 Sep 2;14(9):1078.
   41. Imam SS. The future of non-invasive ways to treat cancer. Int J Pharm Sci & Res. 2021; 12(8): 4684-96.
   42. Imam SS, Agarwal S. A Pragmatic Approach To Treat Lung Cancer Through Loading Theaflavin -3,3’-Digallate And Epigallocatechin Gallate In Spanlastic. Asian J Pharm Clin Res. 2021 Nov 7; 14(11): 1-8.
   43. Imam SS, Imam ST, Mdwasifathar, Kumar R, Ammar MY. Interaction Between Ace 2 And Sars-Cov2, And Use Of EGCG And Theaflavin To Treat Covid 19 In Initial Phases. International Journal of Current Pharmaceutical Research. 2022 Mar; 14(2):5- 10.
   44. Imam SS, Sharma R. Natural compounds promising way to treat Lung Cancer. International Journal of Pharmaceutical Research and Applications. 2023; 8(2): 552- 558.
   45. Imam SS, Sharma S, Kumari D, Khan S, Pathak P, Katiyar D. An Expedient Approach to Treat Asthma through Non-Steroidal, Natural Transferosomes Aerosol System. Innovare journal of medical sciences. 2022; 10(6): 7-11.
   46. Imam SS, Imam ST, Agarwal S, Kumar R, Ammar MY, Athar MW, Akthar A. Lung Cancer Therapy Using Naturally Occurring Products and Nanotechnology. Innovare journal of medical sciences. 2022; 10(4): 1-5.
   47. Imam ST, Imam SS. The Cream which relieves the pain of Menstrual cramps without interfering with the Hormones or Period Cycle. Research Journal of Pharmacy and Technology. 2023; 16(3):1239-6.
   48. Imam SS. Topical Formulation Constituted with Transferosomes for the Treatment Of Non-Melanoma Skin Cancer. Asian J Pharm Clin Res. 2023 May 7;16(5):27-32.
   49. IMAM SS. NANOPARTICLES: THE FUTURE OF DRUG DELIVERY. Int J Curr Pharm Sci. 2023 Nov. 15;15(6):8-15.
   50. Imam SS, Mehdi S, Mansuri A. A COMPREHENSIVE REVIEW ON THE PHARMACOLOGICAL POTENTIAL OF RED GINSENG OIL, TEA TREE OIL AND HEMP SEED OIL. European Journal of Biomedical. 2024;11(4):167-77.
   51. Imam SS. Sublingual Tablets Amalgamated with Nano-particles and natural products to treat Oral Cancer. 2024; 17(5): 2056-62.
   52. Imam SS, Mehdi S. Factors Affecting Pharmaceutical Pricing In India. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES. 2024;2(4):1367-1384. DOI: 10.5281/zenodo.11314004.
   53. Mehdi S, Tabrez UZ, Imam SS. Management of Green Pharmaceuticals. International Journal of Pharmaceutical Sciences And Research. 2024;15(7):1951-1962. DOI: 10.13040/IJPSR.0975-8232.15(7).1951-62.
   54. Imam SS. EVALUATING THE IMPACT OF US TARIFFS AND EVOLVING GLOBAL TRADE POLICIES ON PHARMACEUTICAL PRICING, MARKET PENETRATION, AND THE SUPPLY OF GENERIC MEDICINES FROM INDIA TO THE WORLD. Journal of Pharmacoeconomics and Pharmaceutical Management. 2025 Nov 7;11(2):27-34.
   55. Imam SS. Pharmaceutical Marketing Management in India. Journal of Pharmacoeconomics and Pharmaceutical Management. 2024 Oct 23;10(2):37-48.
   56. de Lima EP, Laurindo LF, Catharin VC, Direito R, Tanaka M, Jasmin Santos German I, Lamas CB, Guiguer EL, Araújo AC, Fiorini AM, Barbalho SM. Polyphenols, alkaloids, and terpenoids against neurodegeneration: evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence. Metabolites. 2025 Feb 13;15(2):124.
   57. Ristori S, Bertoni G, Bientinesi E, Monti D. The role of nutraceuticals and functional foods in mitigating cellular senescence and its related aspects: A key strategy for delaying or preventing aging and neurodegenerative disorders. Nutrients. 2025 May 28;17(11):1837.
   58. Centonze M, Aloisio Caruso E, De Nunzio V, Cofano M, Saponara I, Pinto G, Notarnicola M. The antiaging potential of dietary plant-based polyphenols: A review on their role in cellular senescence modulation. Nutrients. 2025 May 19;17(10):1716.
   59. Kibibi Wairimu H. Narrative Review of Plants in Neurodegenerative Disorders.
   60. Moise G, Jîjie AR, Moacă EA, Predescu IA, Dehelean CA, Hegheș A, Vlad DC, Popescu R, Vlad CS. Plants’ impact on the human brain—exploring the neuroprotective and neurotoxic potential of plants. Pharmaceuticals. 2024 Oct 7;17(10):1339.
   61. Gutiez RM, G JT. Narrative review: Edible plants as a source of valuable flavonoids and their role as neuroprotector agents. Current Nutrition & Food Science. 2023 May 1;19(4):442-60.
   62. Luo L. Promoting cognitive health through the nexus of gut microbiota and dietary phytochemicals. Frontiers in Nutrition. 2025 Aug 29;12:1636131.
   63. Pandey KB, Suttajit M, editors. Plant bioactives as natural panacea against age-induced diseases: nutraceuticals and functional lead compounds for drug development. Elsevier; 2022 Oct 17.
   64. Ali A, Babar Q, Saeed A, Sergi D, Naumovski N, Mohamed Ahmed IA, Shamlan G, Hafiz HA, Manzoor MF, Trafialek J, Madilo FK. Emerging links between ferroptosis and neurodegeneration: implications for disease mechanisms and nutraceutical interventions. Food Science & Nutrition. 2025 Jun;13(6):e70385.
   65. Oyovwi MO, Chijiokwu EA, Ben-Azu B, Atere AD, Joseph UG, Ogbutor UG, Udi OA. Potential roles of natural antioxidants in modulating neurodegenerative disease pathways. Molecular Neurobiology. 2025 Aug;62(8):10367-97.
   66. Babich O, Larina V, Ivanova S, Tarasov A, Povydysh M, Orlova A, Strugar J, Sukhikh S. Phytotherapeutic approaches to the prevention of age-related changes and the extension of active longevity. Molecules. 2022 Mar 31;27(7):2276.
   67. Satyam SM, Bairy LK. Neuronutraceuticals combating Neuroinflammaging: Molecular insights and translational challenges—A systematic review. Nutrients. 2022 Jul 23;14(15):3029.
   68. Muzaffer U, Gull B, Ahmed Z, Ahmad M. Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal. Current Neuropharmacology. 2025 Dec;23(14):1816-40.
   69. Ahmad SS, Khalid M, Kamal MA, Younis K. Study of nutraceuticals and phytochemicals for the management of Alzheimer’s disease: A review. Current neuropharmacology. 2021 Nov 1;19(11):1884-95.
   70. Pekdemir B, Raposo A, Saraiva A, Lima MJ, Alsharari ZD, BinMowyna MN, Karav S. Mechanisms and potential benefits of neuroprotective agents in neurological health. Nutrients. 2024 Dec 18;16(24):4368.
   71. Asdaq SM, Almutiri AA, Alenzi A, Shaikh M, Shaik MA, Alshehri S, Rabbani SI. Unveiling the neuroprotective potential of date palm (Phoenix dactylifera): A systematic review. Pharmaceuticals. 2024 Sep 17;17(9):1221.
   72. Rehman MU, Wali AF, Ahmad A, Shakeel S, Rasool S, Ali R, Rashid SM, Madkhali H, Ganaie MA, Khan R. Neuroprotective strategies for neurological disorders by natural products: an update. Current neuropharmacology. 2019 Mar 1;17(3):247-67.
   73. Basha S, Ks P, Chattopadhyay A, Ramakrishna Pai A, Kishore Mahato K. Emerging insights into dairy products and Alzheimer’s disease: exploring the potential neuroprotective effects. Critical Reviews in Food Science and Nutrition. 2025 Oct 27:1-28.
   74. Onaolapo OJ, Onaolapo AY. Herbs with Nootropic Efficacy. InPlant-based Foods and their Implications in Brain Health 2024 Dec 23 (pp. 95-111). CRC Press.
   75. Nadeem M, Khan MA, Ahmad FJ, Parvez S, Akhtar M, Najmi AK. Exploring the neuroprotective role of asparagus racemosus (Shatavari) in alzheimer’s disease: mechanisms, evidence, and future directions. 3 Biotech. 2025 Jul;15(7):197.
   76. KUMAR R, KAMBOJ N, GUNSOLA D, KARMAKAR R, CHATTARAJ S, GANGOLA S, MUDGAL B, VERMA D, GURURANI P, RATHI N, SINGH R. Current Research in Nutrition and Food Science.
   77. Mujinya R, Terkimbi SD, Oka VO, Ekon ME, Wusa M, Owembabazi E, Maduabuchi PA, Owu DU. The protective role of flavonoids in amnesia-systematic review. F1000Research. 2025 Jul 21;14:716.
   78. Kothawade SM, Buttar HS, Tuli HS, Kaur G. Therapeutic potential of flavonoids in the management of obesity-induced Alzheimer’s disease: an overview of preclinical and clinical studies. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023 Nov;396(11):2813-30.
   79. Semwal P, Rauf A, Olatunde A, Singh P, Zaky MY, Islam MM, Khalil AA, Aljohani AS, Al Abdulmonem W, Ribaudo G. The medicinal chemistry of Urtica dioica L.: from preliminary evidence to clinical studies supporting its neuroprotective activity. Natural Products and Bioprospecting. 2023 Dec;13(1):16.
   80. Kato Jumba K. Neurotoxicity and Diabetes: Mechanistic Insights into Oxidative Stress Mediated Neuronal Damage and Potential Neuroprotective Interventions.
   81. Pereira L, Valado A. Neurological Benefits of Seaweed-Derived Compounds. Marine Drugs. 2026 Jan 8;24(1):31.
   82. Bilski R, Dąbkowski S, Kozieł I, Kozicki M, Małachowska A, Przygocki M, Tyska O. Perspectives on Alzheimer’s Disease Treatment Based on Counteracting Oxidative Stress. Biomolecules. 2025 Sep 19;15(9):1345.
   83. Caruso G, Godos J, Privitera A, Lanza G, Castellano S, Chillemi A, Bruni O, Ferri R, Caraci F, Grosso G. Phenolic acids and prevention of cognitive decline: Polyphenols with a neuroprotective role in cognitive disorders and Alzheimer’s disease. Nutrients. 2022 Feb 15;14(4):819.
   84. Figueiredo Godoy AC, Frota FF, Araújo LP, Valenti VE, Pereira ED, Detregiachi CR, Galhardi CM, Caracio FC, Haber RS, Fornari Laurindo L, Tanaka M. Neuroinflammation and natural antidepressants: balancing fire with flora. Biomedicines. 2025 May 7;13(5):1129.
   85. Şimşek H, Uçar A. Polyunsaturated fatty acids as a nutraceutical for age-related neurodegenerative diseases: Current knowledge and future directions. Clinical nutrition open science. 2024 Aug 1;56:65-73.